Dopamine re-uptake inhibitors show inconsistent effects on the in vivo release of dopamine as measured by intracerebral dialysis in the rat.
The effects of the dopamine (DA) re-uptake blockers amfonelic acid and GBR 12909 on the in vivo release of DA were investigated. DA release was measured by means of a fully automated brain dialysis system. GBR 12909 induced a 3-fold increase in the output of DA; amfonelic acid was without effect. These results indicate a dissociation between the behavioural effects of DA re-uptake blockers and the effects on DA release. A strong synergistic rise of DA release was observed when haloperidol was co-administered with amfonelic acid or GBR 12909. The potentiation of DA release was completely prevented by infusion of 1 microM tetrodotoxin.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001923:Brain Chemistry; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D003956:Dialysis; D004298:Dopamine / Q000378:metabolism*; D006220:Haloperidol / Q000494:pharmacology; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D009268:Nalidixic Acid / Q000031:analogs & derivatives; D009287:Naphthyridines / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains
D009287:Naphthyridines; D010879:Piperazines; D015102:3,4-Dihydroxyphenylacetic Acid; D009268:Nalidixic Acid; C043425:vanoxerine; D006220:Haloperidol; C006486:amfonelic acid; D004298:Dopamine; D006719:Homovanillic Acid